CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Modus Therapeutics Holding AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Modus Therapeutics Holding AB
Olof Palmes gata 29 IV
STOCKHOLM, 111 22  Sweden Ticker: MODTXMODTX

Business Summary
Modus Therapeutics Holding AB is a Sweden-based biotechnology company that through the patented polysaccharide sevuparin develops the treatment for severe diseases with large residual medical needs. The company's focus in the short term is to develop sevuparin for patients with sepsis / septic shock, a serious and often fatal condition. Sevuparin is a state-of-the-art patented polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregated effects. Sevuparin is a heparinoid with markedly weakened anticoagulant function that allows significantly higher doses to be given compared to regular heparinoids, without the risk of bleeding side effects.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2022Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board ViktorDrvota 58 1/1/2016 1/1/2016
Chief Executive Officer JohnOhd 52 1/1/2020 1/1/2020
Chief Financial Officer ClaesLindblad 56 1/1/2021 1/1/2021
Independent Board Member Ellen K.Donnelly 49 1/1/2020 1/1/2020
Independent Board Member TorstenGoesch 64 1/1/2014 1/1/2014

Subsidiaries
Business Name Address City State/Province Country
Modus Therapeutics AB Sankt Eriksgatan 117 STOCKHOLM Sweden

Business Names
Business Name
MODTX
Modus Therapeutics AB

General Information
Outstanding Shares: 35,938,899 (As of 12/31/2023)
Stock Exchange: STO


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024